Open -Label Phase IIa Trial of the Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma
In vitro data indicate that statins affect myeloma cells, mainly by inducing cell death and
growth suppression.
This is a national, multicenter, phase IIa, single arm (not controlled), open label clinical
trial of Simvastatin 80mg p.o. /day in a population of patients with progressive SMM.
Patients will be treated with Simvastatin 40 mg and if no side effect will be seen the dose
will be escalated to 80 mg for up to 18 months. All further treatment decisions after
completion of the study are at the discretion of the investigator.Approximately 15 patients
will be enrolled.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Paraprotein level
18 months
Michael Lishner, MD
Principal Investigator
Meir Medical Center
Israel: Ministry of Health
PSMMSS-01
NCT00503763
September 2007
March 2009
Name | Location |
---|